Treatment Algorithm and Patient Risk Stratification for Early Relapse Management

Dr. Nooka presents a comprehensive treatment algorithm for 100 patients with relapsed multiple myeloma, providing clear risk-based stratification. Among these patients, 30% have high-risk cytogenetics requiring immediate treatment upon biochemical relapse without delay. An additional 10% represent functionally high-risk patients who progress more rapidly than expected based on their clinical trajectory, even without genetic high-risk features. For each patient, Dr. Nooka maintains expected progression-free survival benchmarks, and when these expectations aren't met, it triggers consideration for more aggressive interventions.

Another 10% of patients require immediate treatment due to symptomatic progression, including those presenting with significant bone lesions or organ dysfunction such as kidney failure, regardless of their underlying risk stratification. This creates a cohort of 50% of patients requiring urgent treatment initiation without delay.

The remaining 50% of patients offer the "liberty or luxury of waiting," allowing for careful disease observation and patient assessment. Dr. Nooka emphasizes the predictability of disease behavior in most cases, citing personal experience with patients monitored for extended periods, including one patient observed for ten years before treatment initiation. However, this approach requires vigilant monitoring with monthly laboratory assessments to ensure disease control.

For patients requiring immediate intervention who would benefit from CAR-T but cannot wait 2-3 months due to aggressive disease progression and high attrition rates, bispecific antibodies provide an ideal solution. These "off-the-shelf" therapies can be initiated immediately when treatment decisions are made, filling the critical gap for patients who cannot wait for CAR-T preparation.

For the 50% of patients without urgency who are not CAR-T candidates or interested, Dr. Nooka advocates that by 2026, all should receive bispecific antibody combinations with daratumumab based on the MajesTEC-3 trial, which he considers the most impactful trial in early relapse myeloma management.